Table 3

Reduction (improvement) from Baseline in WOMAC Pain. N (%)

0.03 mg

(N = 7)

0.1 mg

(N = 6)

0.3 mg

(N = 6)

1 mg

(N = 6)

All

(N = 25)

Placebo

(N = 8)


Mean Baseline Score (0-20)

7.57

10.5

8.2

8.33

8.6

8.6


Week 4

20% Reduction

3 (42.9%)

3 (50.0%)

2 (33.3%)

5 (83.3%)

13 (52%)

1 (12.5%)


Week 8

20% Reduction

3 (42.9%)

5 (83.3%)

3 (50.0%)

5 (83.3%)

16 (64%)

3 (37.5%)


Week 12

20% Reduction

4 (57.1%)

5 (83.3%)

3(50.0%)

1 (16.7%)

13 (52%)

4 (50.0%)


Week 24

20% Reduction

4 (57.1%)

5 (83.3%)

5 (83.3%)

1 (16.7%)

15 (60%)

4 (50.0%)


Week 4

50% Reduction

3 (42.9%)

2 (33.3%)

2 (33.3%)

3 (50.0%)

10 (40%)

0 (0.0%)


Week 8

50% Reduction

1 (14.3%)

3 (50.0%)

3 (50.0%)

4 (66.7%)

11 (44%)

0 (0.0%)


Week 12

50% Reduction

0 (0.0%)

3 (50.0%)

2 (33.3%)

1 (16.7%)

6 (24%)

1(12.5%)


Week 24

50% Reduction

0 (0.0%)

5 (83.3%)

3 (50.0%)

1 (16.7%)

9 (36%)

0 (0.0%)


Week 4

70% Reduction

1 (14.3%)

1 (16.7%)

2 (33.3%)

1 (16.7%)

5 (20%)

0 (0.0%)


Week 8

70% Reduction

1 (14.3%)

1 (16.7%)

2 (33.3%)

1 (16.7%)

5 (20%)

0 (0.0%)


Week 12

70% Reduction

0 (0.0%)

2 (33.3%)

2 (33.3%)

0 (0.0%)

4 (16%)

0 (0.0%)


Week 24

70% Reduction

0 (0.0%)

3 (50.0%)

3 (50.0%)

0 (0.0%)

6 (24%)

0 (0.0%)


Hunter et al. BMC Musculoskeletal Disorders 2010 11:232   doi:10.1186/1471-2474-11-232

Open Data